Dr. Goldkorn earned his medical degree from the UCLA School of Medicine. He then went on to complete his fellowship in hematology-oncology and post-doctoral research at University of California, San Francisco.
American Federation for Medical Research: Outstanding Investigator Award, 2015
Western Society of Clinical Investigation: Elected Member, 2014
American Society of Clinical Oncology: Merit Award, 2012
Stop Cancer Foundation: Research Career Development Award, 2007-2010
American Society of Clinical Oncology: Young Investigator Award, 2006-2007
UCLA School of Medicine: Letters of Distinction, 1996-1997
Harvard University: Harvard College Scholarship, 1990-1994
Multi-parametric liquid biopsy analysis in metastatic prostate cancer JCI Insight. 2019 Jan 31. . View in PubMed
A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors Cancer Chemother Pharmacol. 2018 Oct; 82(4):723-732. . View in PubMed
A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors Cancer Chemother Pharmacol. 2018 Aug 20. . View in PubMed
Development of a translational medicine protocol for an NCTN genitourinary clinical trial: Critical steps, common pitfalls and a basic guide to translational clinical research Urol Oncol. 2018 Aug 13. . View in PubMed
Development and Application of Liquid Biopsies in Metastatic Prostate Cancer Curr Oncol Rep. 2018 Mar 23; 20(4):35. . View in PubMed
Liquid Biopsy in Prostate Cancer: Circulating Tumor Cells and Beyond Cancer Treat Res. 2018; 175:87-104. . View in PubMed
Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421 Clin Genitourin Cancer. 2017 Dec; 15(6):635-641. . View in PubMed
Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421 Clin Genitourin Cancer. 2017 12; 15(6):635-641. . View in PubMed
Circulating Tumor Cells in Genitourinary Malignancies: An Evolving Path to Precision Medicine Front Oncol. 2017; 7:6. . View in PubMed
Telomere and Telomerase Therapeutics in Cancer Genes (Basel). 2016 May 26; 7(6). . View in PubMed
AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth Prostate. 2016 May; 76(6):597-608. . View in PubMed
Editorial Comment J Urol. 2015 Sep; 194(3):798. . View in PubMed
Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy J Natl Cancer Inst. 2015 Jul; 107(7). . View in PubMed
Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial Int J Cancer. 2015 Apr 15; 136(8):1856-62. . View in PubMed
Circulating tumor cells in prostate cancer: a better predictor of survival than prostate specific antigen? Expert Rev Anticancer Ther. 2014 Nov; 14(11):1257-60.. View in PubMed
New prostate cancer drugs: extending and improving life Lancet Oncol. 2014 Sep; 15(10):1052-4. . View in PubMed
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer J Clin Oncol. 2014 Apr 10; 32(11):1136-42. . View in PubMed
Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421 J Natl Cancer Inst. 2014 Apr; 106(4):dju013. . View in PubMed
Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/ß-catenin/CBP pathway Int J Cancer. 2014 Jan 01; 134(1):43-54. . View in PubMed
Circulating tumor cells in prostate cancer Cancers (Basel). 2013 Dec 04; 5(4):1676-90. . View in PubMed
Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer Clin Genitourin Cancer. 2013 Dec; 11(4):416-22. . View in PubMed
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial Lancet Oncol. 2013 Aug; 14(9):893-900. . View in PubMed
Perillyl alcohol for the treatment of temozolomide-resistant gliomas Mol Cancer Ther. 2012 Nov; 11(11):2462-72. . View in PubMed
Prostate tumor cells with cancer progenitor properties have high telomerase activity and are rapidly killed by telomerase interference Prostate. 2011 Sep 15; 71(13):1390-400. . View in PubMed
Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic of a cancer stem-like phenotype Mol Cancer Ther. 2011 Jun; 10(6):938-48. . View in PubMed
Telomerase targeted therapy in cancer and cancer stem cells Clin Adv Hematol Oncol. 2011 Jun; 9(6):442-55. . View in PubMed
A cancer detection platform which measures telomerase activity from live circulating tumor cells captured on a microfilter Cancer Res. 2010 Aug 15; 70(16):6420-6. . View in PubMed
Reprogramming murine telomerase rapidly inhibits the growth of mouse cancer cells in vitro and in vivo Mol Cancer Ther. 2010 Feb; 9(2):438-49. . View in PubMed
Targeted therapy in renal cancer Ther Adv Med Oncol. 2009 Nov; 1(3):183-205. . View in PubMed
Assembly of mutant-template telomerase RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres is required for apoptosis and cell cycle arrest in human cancer cells Cancer Res. 2006 Jun 01; 66(11):5763-71. . View in PubMed
